Grant: Master's Award: Canada Graduate Scholarships
University of British Columbia
$17,500.00
Investigating the mechanism of Peutz-Jeghers Syndrome development.
EF 2018-19
Résumé
Peutz-Jeghers Syndrome (PJS) is a genetic disorder caused by deficiencies in the Liver Kinase B1 (LKB1) protein. Patients experience chronic inflammation and benign tumor growth along their gastrointestinal (GI) tract, and have a 90% chance of developing cancer by age 65.
T cells are part of the adaptive immune system, and either promote or dampen inflammation. We previously discovered that T cell-specific LKB1 deficiencies (LT) are sufficient to induce PJS in mice; however, a subset of these LT mice develop no disease and appear normal. This suggests that inflammation and tumor growth are not intrinsic results of an LKB1-deficient genotype, but require an environmental trigger. The proposed research will investigate whether pro-inflammatory gut-microbiome interactions may trigger an immune response that cannot be adequately dampened, leading to a pro-cancerous, chronic inflammatory state.
There are 3 proposed study objectives. Firstly, it is well established that changes in gut microbiome composition are strongly associated with intestinal disease. The microbiome compositions of LT mice will thus be determined and compared to elucidate any differences between a diseased and a non-diseased state. Secondly, Th17 (pro-inflammatory T) cells will be over- and under-expressed in LT mice to determine whether their expression drives PJS development. Lastly, if objective 1 shows observable differences in the microbiomes, young LT mice will be inoculated with diseased and non-diseased microbiomes to determine whether their composition directly modulates disease severity.
Current therapies for PJS focus on symptomatic treatment, but understanding the disease mechanism would allow the development of preventative therapies that reduce inflammation and improve prognosis.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
British Columbia, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
406303
Name
Metcalfe-Roach Avril
Region
British Columbia
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Investigating the mechanism of Peutz-Jeghers Syndrome development.
Programtype2
Studentship Programs
Orgnameinp2
University of British Columbia
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Bioinformatics; Cancer; Colitis; Disease; Gastrointestinal; Immunology; Inflammation; Microbiology; Polyposis; T Cell
Abstract
Peutz-Jeghers Syndrome (PJS) is a genetic disorder caused by deficiencies in the Liver Kinase B1 (LKB1) protein. Patients experience chronic inflammation and benign tumor growth along their gastrointestinal (GI) tract, and have a 90% chance of developing cancer by age 65.
T cells are part of the adaptive immune system, and either promote or dampen inflammation. We previously discovered that T cell-specific LKB1 deficiencies (LT) are sufficient to induce PJS in mice; however, a subset of these LT mice develop no disease and appear normal. This suggests that inflammation and tumor growth are not intrinsic results of an LKB1-deficient genotype, but require an environmental trigger. The proposed research will investigate whether pro-inflammatory gut-microbiome interactions may trigger an immune response that cannot be adequately dampened, leading to a pro-cancerous, chronic inflammatory state.
There are 3 proposed study objectives. Firstly, it is well established that changes in gut microbiome composition are strongly associated with intestinal disease. The microbiome compositions of LT mice will thus be determined and compared to elucidate any differences between a diseased and a non-diseased state. Secondly, Th17 (pro-inflammatory T) cells will be over- and under-expressed in LT mice to determine whether their expression drives PJS development. Lastly, if objective 1 shows observable differences in the microbiomes, young LT mice will be inoculated with diseased and non-diseased microbiomes to determine whether their composition directly modulates disease severity.
Current therapies for PJS focus on symptomatic treatment, but understanding the disease mechanism would allow the development of preventative therapies that reduce inflammation and improve prognosis.
Competitiondate
201812
Approvedterm2
1 yr 0 mth
Pinamesdelim
Metcalfe-Roach, Avril
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~